Background: Postoperative delirium occurs frequently in elderly hip fracture surgery patients and is associated with poorer overall outcomes. Because xenon anaesthesia has neuroprotective properties, we evaluated its effect on the incidence of delirium and other outcomes after hip fracture surgery. Methods: This was a phase II, multicentre, randomized, double-blind, parallel-group, controlled clinical trial conducted in hospitals in six European countries (September 2010 to October 2014). Elderly (!75yr-old) and mentally functional hip fracture patients were randomly assigned 1:1 to receive either xenon-or sevoflurane-based general anaesthesia during surgery. The primary outcome was postoperative delirium diagnosed through postoperative day 4. Secondary outcomes were delirium diagnosed anytime after surgery, postoperative sequential organ failure assessment (SOFA) scores, and adverse events (AEs). Results: Of 256 enrolled patients, 124 were treated with xenon and 132 with sevoflurane. The incidence of delirium with xenon (9.7% [95% CI: 4.5 -14.9]) or with sevoflurane (13.6% [95% CI: 7.8 -19.5]) were not significantly different (P¼0.33). Overall SOFA scores were significantly lower with xenon (least-squares mean difference: À0.33 [95% CI: À0.60 to À0.06]; P¼0.017). For xenon and sevoflurane, the incidence of serious AEs and fatal AEs was 8.0% vs 15.9% (P¼0.05) and 0% vs 3.8% (P¼0.06), respectively. Conclusions: Xenon anaesthesia did not significantly reduce the incidence of postoperative delirium after hip fracture surgery. Nevertheless, exploratory observations concerning postoperative SOFA-scores, serious AEs, and deaths warrant further study of the potential benefits of xenon anaesthesia in elderly hip fracture surgery patients. Clinical trial registration: EudraCT 2009-017153-35; ClinicalTrials.gov NCT01199276.
Postoperative delirium is common in the elderly and is associated with poor outcome. Xenon has been shown to have neuroprotective properties in animal studies. This study found no evidence that xenon-based anaesthesia reduced the incidence of delirium after hip fracture surgery in the elderly. This study is likely to be underpowered, so beneficial effects of xenon may have gone undetected.
With an ever-aging population, hip fracture is a major medical problem that imposes huge medical, financial, and societal burdens, and impairs the quality of life for patients, careproviders, and care-givers. 1, 2 In the UK alone, there were over 67 000 hip fractures reported in 2014. 3 Hip fracture is also associated with high 30-day mortality rates (8 À 10% in the UK) and high one-yr mortality rates, which were reported to be 19 À 40% across several European countries. 3, 4 Postoperative delirium (POD) is also strongly associated with hip fracture surgery in older patients, with reported incidence rates of 13 À 50%. 5e10 POD is an acute state of confusion associated with changes in the levels of consciousness, arousal, and cognition after surgery. 11 While usually short-lived, POD is associated with increased hospital stays and costs, higher morbidity and mortality, higher risks of institutionalisation, cognitive decline, dementia, and poorer overall outcomes. 5,12e14 The aetiology of POD is complex, poorly understood, and multifactorial. 15, 16 The risk of POD increases with age, preexisting cognitive impairment, dementia, depression, comorbidity and vascular disease. 11, 16, 17 Recent data support the proposal that POD is a cognitive disintegration with a breakdown in neural network connectivity, possibly mediated through an increase in inhibitory g-amino-butyric acid (GABA)-ergic tone, resulting in impaired integration of information in frontoparietal networks. 15, 18 Indeed, many of the modifiable risk factors for POD interact with GABAergic signaling. 11, 15, 17, 19, 20 The noble gas xenon is an anaesthetic that blocks Nmethyl-D-aspartate receptors and activates two-pore-domain potassium channels but has no activity on GABA receptors. 21e23 Xenon has been demonstrated to exert organoprotective effects including neuro-and cardio-protection, and to maintain haemodynamic stability better than other anaesthetics. 21e30 In two small studies in cardiac surgery patients, xenon has exhibited potentially promising, though inconsistent, effects in preventing POD. 29, 31 However, neither study was designed or powered to specifically address the prevention of POD by xenon. As a result of the potentially beneficial qualities of xenon, we hypothesized that the incidence of POD in hip fracture surgery patients would be lower with xenon-based anaesthesia than with sevoflurane-based anaesthesia. We therefore conducted a clinical trial to specifically compare the incidence of POD and other outcomes in hip fracture surgery patients anaesthetized with either xenon or sevoflurane.
Methods

Study design
The design and protocol of the study have been published previously 32 and are summarized in the Supplementary material.
Briefly, this was a phase II, observer-blinded, parallel-arm, multicentre, randomized controlled trial conducted at 13 university or tertiary hospitals in six European countries (France, Belgium, Germany, Spain, UK, and Italy) between September 2010 and October 2014. The study protocol and subsequent substantial amendments were approved by local independent ethics committees and the competent regulatory authority in each country for each investigational site. During the course of the study, there were several protocol amendments. As a result of enrolment that was slower than anticipated with five centres, the recruitment period was extended on four successive occasions, and eight study sites were added to achieve the target enrolment (one in Belgium, five in France, and two in Germany). The collection of survival information at 28-days post-surgery was also added because it was identified as a key outcome parameter in the UK's National Hip Fracture Database. 3 
Participants
Hip fracture patients!75 yr old with planned surgery within 48 h of fracture were eligible for study participation. Notable exclusion criteria included a history of severe dementia, Alzheimer's disease, schizophrenia, or moderate to severe depression; a recent brain trauma or history of stroke; delirium, as determined by a shortened version of the Confusion Assessment Method (CAM), 33 
Procedures
Patients were randomly assigned to the xenon or sevoflurane treatment groups using a blocked randomization scheme stratified by centre, with a block size of six, and assigned to groups from a computer-generated list. Block size was not specified in the protocol nor communicated to the investigators to avoid predictability of the next treatment. Patient selection and follow-up visits and assessments were performed by a study physician who was blinded to the allocated anaesthetic (Physician 1). After weaning from anaesthesia, vital signs, recovery parameters, and the Aldrete score were monitored every 15 min until recovery was complete with a score of ! 9. Beginning at 3 h after surgery and at twice-daily visits [10 am (30min) and 6 pm (30 min)] through discharge (or for a maximum of 28 days), patients were assessed for POD, severity of pain (VAS), vital signs, concomitant medications, adverse events (AEs), and serious adverse events (SAEs). SOFA scores and laboratory analysis results were recorded at each visit through day four and were optional thereafter.
Outcomes
The primary endpoint was the occurrence of at least one episode of POD as assessed by the shortened worksheet version of the CAM within four days post-surgery. This worksheet includes the first four criteria of the full CAM, all of which are necessary and sufficient for detecting delirium. 33 The CAM assessment was performed by investigators (Physician 1 or a research nurse), who were blinded to the group assignment and who received extensive and specific training before the study according to the CAM training manual and coding guide. 34 Training was conducted by an external studysponsored physician via a remote presentation during study site initiation. Secondary exploratory endpoints were POD from postoperative day five through discharge; SOFA on postoperative days one to four; recovery parameters; and mortality. Safety was assessed from the AEs and SAEs recorded throughout the study and from laboratory parameters. Diagnostic criteria for specific AEs were those used in standard practice at each study site and were not harmonised across the study sites.
Statistical analysis
The sample size was calculated based on an expected POD event rate of 30% within four days after surgery with sevoflurane anaesthesia. 32 It was estimated that this POD event rate would be 50% lower with xenon yielding an event rate of 15%. We estimated a large effect size (odds ratio of 0.50) for this older population, which is larger than what would be considered as a clinically significant improvement. Type I error was set to a ¼ 0.05 (two-sided conditions), and power was 80% to detect the 50% reduction. Power calculations were performed using nQuery Advisor ® Version 6.01 (Statistical Solutions, Saugus, MA) and yielded 121 patients per group. With an expected dropout rate of 5%, the target enrolment was set to 256 randomized patients (128 per group).
In the primary analysis of the primary outcome, the POD incidence within four days post-surgery in each group in the intention-to-treat population was compared using a c 2 test that included observed cases only. The Pearson's analysis was also repeated for the per-protocol population (patients with no major protocol deviations) in sensitivity analyses and to handle missing data. Sensitivity, secondary, exploratory, and post-hoc analyses are described in the Supplementary material. Statistical analyses were performed using SAS ® software (SAS Institute, Cary, NC, USA) Version 9.2. Statistical significance for all tests was fixed at a ¼ 0.05. However, a value of a ¼ 0.10 was applied during the initial two-factor regression analysis to identify potentially confounding factors to be used in the subsequent multivariate regression analysis, and during the stepwise backward selection of these factors in the multivariate regression model.
Results
From over 2000 hip fracture patients screened for the study, only 268 were enrolled and 260 were randomly assigned to the treatment groups between September 2010 and October 2014 ( Fig. 1 ). Most pre-enrolment exclusions were because of low MMSE scores. Among these, 256 randomized patients were treated and eligible for analysis. Fourteen patients who had major protocol deviations were included in the intention-totreat population but were excluded from per-protocol analyses. Most were excluded for multiple (!five) missing CAM evaluations (nine patients) after surgery or for missing CAM evaluations at selection (three patients). A total of 110 patients in the xenon group and 120 in sevoflurane group completed the study.
Patient population
Baseline characteristics were similar for both groups (Table 1) . Most patients in each group were women and the mean age was 84 yr. Most patients had an ASA physical status of II or III and a moderate level of pain. Pre-operative SOFA scores were Among the over 2000 patients who were screened for enrolment in the HIPELD study, 268 were enrolled. Records were not kept for patients not enrolled, but most of these patients failed to meet the MMSE score criterion. Of the enrolled patients, 260 patients were eventually randomly assigned and 257 were treated and followed for safety. One non-randomized patient was treated with xenon anaesthesia and included in the safety population but was not included in any other analyses and did not complete the study (*). Most patients excluded from the per-protocol analyses had multiple missing CAM evaluations (nine patients).
low; however, concomitant diseases such as hypertension, cardiac disorders, and musculoskeletal disorders were frequent (95%).
Hip fracture surgeries and anaesthesia
Surgery-related data and duration of the procedures were similar for the two groups (Table 2 ). During recovery from anaesthesia, the times to open eyes, to react to verbal commands, and to extubation were all significantly shorter for xenon than for sevoflurane (P<0.001). The time to reach an Aldrete score of nine was similar for both groups. Total length of hospital stay was similar for both groups, and >95% of the patients in each group were discharged from the hospital within 30 days after surgery. Depth of anaesthesia during surgery (BIS values; Supplementary Fig. S1 ) and haemodynamic variables during surgery ( Supplementary Fig. S2 ) were similar across groups.
Postoperative delirium incidence
In the primary analysis, a total of 12 out of 124 (9.7% [95% CI: 4.5 14.9%]) patients in the xenon group vs 18 out of 132 (13.6% [95% CI: 7.8 À19.5%]) patients in the sevoflurane group had at least one POD episode during the first four days after surgery (Table 3 ). These incidence rates were not significantly different Table S1 ). Incidence rates for POD at five or more days after surgery or at any time after surgery were not significantly different (P¼0.46 for each; Table 3 ). Six (4.8%) patients in the xenon group and 11 (8.3%) patients in the sevoflurane group had multiple POD episodes during the study. The mean time to a first POD episode during the first four days after surgery (also the Kaplan-Meier diagram in Supplementary Fig. S3 ) and the mean duration of POD episodes were similar in both groups, with most episodes lasting 0.5 days.
In multivariate-factor logistic regression analyses of patient factors possibly associated with POD within the first four Table S3 ).
SOFA scores
Mean total SOFA scores (SD) increased after surgery and were highest at day 1, with scores of 0. Table 4 ). Most AEs were treatmentemergent and of mild-to-moderate severity, and about 50% in each group were considered by the investigators to be related to study treatment. SAEs were nearly twice as common in the sevoflurane group (45 for 21 patients) than in the xenon group (22 for 10 patients; P¼0.05). The proportion of patients with SAEs that were graded severe was significantly greater in the sevoflurane group than in the xenon group (P¼0.008).
Mortality
Vital status at 28 days after surgery was available for 103 (83%) patients in the xenon group and 110 (83%) patients in the sevoflurane group; no additional deaths were reported. By the end of the study, only one patient in the xenon group and three patients in the sevoflurane group had ongoing SAEs (Table 4) . No patients in the xenon group died but five patients in the sevoflurane group (3.8%) succumbed to fatal SAEs (P¼0.06).
Causes of death were septic shock and multi-organ failure; pneumonia and respiratory failure; pneumonia, septic shock and acute renal failure; right ventricular failure; and cardiac failure. Three of the patients who died had at least one POD episode within four days of surgery.
Discussion
In this international randomized clinical trial, xenon-based anaesthesia did not significantly reduce the incidence of POD in elderly hip fracture surgery patients. Differences in secondary outcomes were either statistically significant and not clinically meaningful in this study (SOFA scores) or potentially clinically pertinent but not statistically significant (SAEs, mortality). The incidence of POD after hip fracture surgery in the elderly is typically high. 5e9, 11 In the studies we used to calculate the sample size needed to evaluate the primary efficacy criterion of at least one POD episode within four days after surgery, the incidence varied between 28% and 50%; 6e10,32,38,39 however, the actual incidence of POD in the sevoflurane control group (13.6%) was much lower than the expected rate (30%). The lower-than-expected incidence of POD in the sevoflurane group likely reflects our use of strict inclusion criteria; patients were excluded for any preoperative signs of delirium, moderate to severe depression, or a poor functional mental state (MMSE score<24). As a consequence, the patient population in the study may have differed from the general elderly population that routinely undergoes hip fracture surgery, in whom the incidence of POD is higher. 13, 16 Indeed, it proved difficult to recruit patients into the study because many patients who fulfilled the other inclusion criteria failed to satisfy the mental state criteria. We estimate that less than 15% of those screened were eligible for enrolment. Another contributing factor to the low incidence of POD may have been the use of BIS technology to monitor the depth of anaesthesia; in a recent meta-analysis, the incidence of POD was found to be lower with BIS-guided anaesthesia than with BIS-blinded anaesthesia or clinical judgment. 40 The POD incidence in the xenon group was not 50% lower than in the sevoflurane group as required by the power analysis, but only 33% lower. Despite this, an overall reduction of 33% in POD, if statistically significant, would still represent a clinically meaningful benefit, which future studies should consider. Nonetheless, the overestimations of both the PODincidence rate and the effect size rendered the power of the study insufficient to detect significant differences between the two groups for the primary efficacy endpoint. Despite the low incidence of POD in the study, we were able to identify two patient factors that were significantly associated with POD: being a current smoker and having a previously diagnosed mild neurologic disorder. 13, 16, 41, 42 The association of POD with the type of anaesthesia or anaesthetic agent used for surgery is unclear. There is some evidence that the incidence of POD may increase with the depth of anaesthesia, but regional anaesthesia was not found to be preventative, perhaps as a result of sedation in the regional anaesthesia group. 19, 43 In a small pilot study in 42 patients who received either xenon or sevoflurane-based anaesthesia during cardiac surgery, the incidence of POD was significantly lower in the group that received xenon 29 ; although these latter results were not confirmed in our hip fracture surgery patients, the potential benefits of xenon in cardiac surgery patients await confirmation in a larger clinical trial. 44 While xenon anaesthesia has previously demonstrated orga-noprotective properties and a superior haemodynamic profile compared with other anaesthetic agents, 22,24e26,29,45,46 we could not confirm these effects in hip fracture surgery patients. Though patients in the xenon-group had a slightly lower overall SOFA score (which could be interpreted as a sign for a certain degree of organoprotection), this difference was of marginal clinical relevance. Likewise, there were no significant differences between the groups in patients with SAEs (P¼0.05) or in patients with fatal SAEs (P¼0.06), though the proportion of patients with SAEs graded as severe was significantly smaller in the xenon group (P¼0.008).
The study has several strengths and limitations. Specific inclusion and exclusion criteria resulted in a well-defined study population that was similar for the prospective risk of developing POD across the treatment groups. The high temporal resolution consequent to the twice-daily CAM evaluations ensured that a high proportion of the POD episodes could be detected. The secondary efficacy endpoints and safety data facilitated assessment of the potential benefits of xenon anaesthesia on organoprotection and mortality. One limitation regarding mortality may be that 28-day follow-up results were available for only~80% of the patients in each group. We did not interrogate death registries to accommodate for missing data. We used BIS technology to avoid variations in and excessively deep anaesthesia during surgery and to prevent depth of anaesthesia from becoming a confounding factor between treatment groups. BIS values were carefully monitored and mean values were consistently maintained and similar during surgery for both groups suggesting that similar levels of consciousness and exposure were obtained for these two different anaesthetics. A major limitation was the low overall incidence of POD, likely because of the restrictive exclusion criteria that eliminated many patients at high risk for developing POD, and may have been additionally reduced through our use of BIS to monitor the depth of anaesthesia. 40 It is also possible that some POD episodes were missed as a result of some inconsistencies in administration of the CAM across different staff and centres and by our use of the shortened, worksheet version of the CAM. Although the full nine-item CAM is recommended for maximum sensitivity, we considered the shorter CAM to be far more practical and reasonable for an international clinical trial using twice-daily postoperative assessments. In addition, the four essential and validated criteria for determining delirium are included in the shortened CAM worksheet. 33, 47 Finally, while some training is recommended for optimal use, 47 and our study personnel received extensive and specific training according the CAM training manual before the study, we cannot be certain that the CAM was administered consistently across all study centres. Indeed, training can be a factor in delirium recognition by the CAM. 48 One aspect of delirium not considered in the current study was severity. The CAM-S tool provides a revised delirium scoring system that allows assessment of delirium severity. 49 Investigators should bear these aspects in mind when designing clinical trials to investigate preventative measures for POD.
Conclusions
The incidence of POD in this study was not significantly lower with xenon anaesthesia than with sevoflurane anaesthesia. Our observations concerning postoperative SOFA-scores, SAEs, and mortality should be considered hypothesis-generating and warrant further study to assess the potential benefits of xenon anaesthesia in elderly hip-fracture surgery patients.
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